Naloxone, flumazenil and dantrolene as antidotes:
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Language: | English |
| Published: |
Cambridge
Cambridge Univ. Press
1993
|
| Edition: | 1. publ. |
| Series: | International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series
1 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XV, 98 S. |
| ISBN: | 052145459X |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV009561261 | ||
| 003 | DE-604 | ||
| 005 | 19940506 | ||
| 007 | t | ||
| 008 | 940502s1993 |||| 10||| engod | ||
| 020 | |a 052145459X |9 0-521-45459-X | ||
| 035 | |a (OCoLC)28749084 | ||
| 035 | |a (DE-599)BVBBV009561261 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a RM302.2 | |
| 082 | 0 | |a 615.9/08 |2 20 | |
| 084 | |a XI 2800 |0 (DE-625)152989:12905 |2 rvk | ||
| 100 | 1 | |a Meredith, T. J. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Naloxone, flumazenil and dantrolene as antidotes |c scientific ed. T. J. Meredith ... |
| 250 | |a 1. publ. | ||
| 264 | 1 | |a Cambridge |b Cambridge Univ. Press |c 1993 | |
| 300 | |a XV, 98 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series |v 1 | |
| 650 | 4 | |a Antidotes | |
| 650 | 4 | |a Antidotes |x therapeutic use | |
| 650 | 4 | |a Dantrolene | |
| 650 | 4 | |a Dantrolene |x therapeutic use | |
| 650 | 4 | |a Drug antagonists | |
| 650 | 4 | |a Flumazenil | |
| 650 | 4 | |a Flumazenil |x therapeutic use | |
| 650 | 4 | |a Naloxone | |
| 650 | 4 | |a Naloxone |x therapeutic use | |
| 650 | 0 | 7 | |a Antidot |0 (DE-588)4142655-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Flumazenil |0 (DE-588)4225907-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Dantrolen |0 (DE-588)4219898-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Naloxon |0 (DE-588)4202897-8 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Antidot |0 (DE-588)4142655-1 |D s |
| 689 | 0 | 1 | |a Dantrolen |0 (DE-588)4219898-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Antidot |0 (DE-588)4142655-1 |D s |
| 689 | 1 | 1 | |a Flumazenil |0 (DE-588)4225907-1 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Antidot |0 (DE-588)4142655-1 |D s |
| 689 | 2 | 1 | |a Naloxon |0 (DE-588)4202897-8 |D s |
| 689 | 2 | |5 DE-604 | |
| 830 | 0 | |a International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series |v 1 |w (DE-604)BV009560031 |9 1 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006318093&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006318093 | ||
Record in the Search Index
| _version_ | 1804123903255117824 |
|---|---|
| adam_text | IPCS/CEC EVALUATION OF ANTIDOTES SERIES VOLUME 1 NALOXONE, FLUMAZENIL
AND DANTROLENE AS ANTIDOTES SCIENTIFIC EDITORS T. J. MEREDITH DEPARTMENT
OF HEALTH, LONDON, UNITED KINGDOM D. JACOBSEN ULLEVAL UNIVERSITY
HOSPITAL, OSLO, NORWAY J. A. HAINES INTERNATIONAL PROGRAMME ON CHEMICAL
SAFETY, WORLD HEALTH ORGANIZATION, GENEVA, SWITZERLAND J-C. BERGER
HEALTH AND SAFETY DIRECTORATE, COMMISSION OF THE EUROPEAN COMMUNITIES,
LUXEMBOURG EUR 14797 EN PUBLISHED BY CAMBRIDGE UNIVERSITY PRESS ON
BEHALF OF THE WORLD HEALTH ORGANIZATION AND OF THE COMMISSION OF THE
EUROPEAN COMMUNITIES CAMBRIDGE UNIVERSITY PRESS CONTENTS PREFACE XIII
ABBREVIATIONS XV 1. INTRODUCTION TO THE SERIES 1 2. NALOXONE 7 2.1
INTRODUCTION 7 2.2 NAME AND CHEMICAL FORMULA 7 2.3 PHYSICO-CHEMICAL
PROPERTIES 8 2.4 PHARMACEUTICAL FORMULATION AND SYNTHESIS 9 2.5
ANALYTICAL METHODS 9 2.5.1 QUALITY CONTROL 9 2.5.2 IDENTIFICATION 9
2.5.3 QUANTIFICATION OF THE ANTIDOTE 9 2.5.4 ANALYSIS OF TOXIC AGENTS 9
2.6 SHELF-LIFE 10 2.7 GENERAL PROPERTIES 10 2.8 ANIMAL STUDIES 10 2.8.1
PHARMACODYNAMICS 10 2.8.2 PHARMACOKINETICS 11 2.8.3 TOXICOLOGY 12 2.9
VOLUNTEER STUDIES . 12 2.9.1 PHARMACOKINETICS 12 2.9.2 PHARMACODYNAMICS
13 2.9.3 EFFECTS OF HIGH DOSES OF NALOXONE 14 2.10 CLINICAL STUDIES -
CLINICAL TRIALS 14 2.10.1 EFFECTS IN THERAPEUTIC USE OF OPIOIDS 14
2.10.2 EFFECTS IN ACUTE OPIOID POISONING 15 2.11 CLINICAL STUDIES - CASE
REPORTS 17 2.11.1 NALOXONE IN CLONIDINE POISONING 17 2.12 SUMMARY OF
EVALUATION 17 2.12.1 INDICATIONS 17 2.12.2 ADVISED ROUTES AND DOSE 17
2.12.3 OTHER CONSEQUENTIAL OR SUPPORTIVE THERAPY 18 2.12.4 AREAS WHERE
THERE IS INSUFFICIENT INFORMATION TO MAKE RECOMMENDATIONS 19 2.12.5
PROPOSALS FOR FURTHER STUDIES 19 2.12.6 ADVERSE EFFECTS 19 VI 2.12.7
RESTRICTIONS OF USE 20 2.13 MODEL INFORMATION SHEET 20 2.13.1 USES 20
2.13.2 DOSAGE AND ROUTE 20 2.13.3 PRECAUTIONS/CONTRAINDICATIONS 21
2.13.4 ADVERSE EFFECTS 21 2.13.5 USE IN PREGNANCY AND LACTATION 21
2.13.6 STORAGE 21 2.14 REFERENCES 21 3. FLUMAZENIL 27 3.1 INTRODUCTION
27 3.2 NAME AND CHEMICAL FORMULA OF ANTIDOTE 27 3.3 PHYSICO-CHEMICAL
PROPERTIES 27 3.4 PHARMACEUTICAL FORMULATION AND SYNTHESIS 27 3.5
ANALYTICAL METHODS 28 3.5.1 IDENTIFICATION OF THE ANTIDOTE 28 3.5.1.1
INFRARED SPECTROSCOPY 28 3.5.1.2 ULTRAVIOLET ABSORPTION 28 3.5.1.3
THIN-LAYER CHROMATOGRAPHY 29 3.5.2 QUANTIFICATION OF THE ANTIDOTE IN
BIOLOGICAL SAMPLES 29 3.5.3 ANALYSIS OF THE TOXIC AGENT IN BIOLOGICAL
SAMPLES 30 3.6 SHELF-LIFE 30 3.7 GENERAL PROPERTIES 30 3.8 ANIMAL
STUDIES 30 3.8.1 PHARMACODYNAMICS 30 3.8.2 PHARMACOKINETICS 31 3.8.2.1
ABSORPTION 31 3.8.2.2 DISTRIBUTION 32 3.8.2.3 ELIMINATION 32 3.8.3
TOXICOLOGY 32 3.8.3.1 ACUTE TOXICITY 32 3.8.3.2 SUBACUTE TOXICITY 34
3.8.3.3 CHRONIC TOXICITY 34 3.8.3.4 EMBRYOTOXICITY 34 3.8.3.5
MUTAGENICITY 34 3.9 VOLUNTEER STUDIES 34 3.9.1 PHARMACODYNAMICS 34
3.9.1.1 BZD ANTAGONIST EFFECT 34 3.9.1.2 INTRINSIC EFFECTS 35 VLL 3.9.2
PHARMACOKINETICS 35 3.9.2.1 ABSORPTION 35 3.9.2.2 DISTRIBUTION 35
3.9.2.3 ELIMINATION 35 3.9.3 TOLERANCE OF FLUMAZENIL 36 3.9.4 OTHER
STUDIES 36 3.10 CLINICAL STUDIES - CLINICAL TRIALS 36 3.10.1
ANAESTHESIOLOGY 36 3.10.1.1 GENERAL ANAESTHESIA 36 3.10.1.2 CONSCIOUS
SEDATION 37 3.10.2 BENZODIAZEPINE OVERDOSE OR INTOXICATION 37 3.11
CLINICAL STUDIES - CASE REPORTS 38 3.12 SUMMARY OF EVALUATION 38 3.12.1
INDICATIONS 38 3.12.2 DOSAGE AND ROUTE 39 3.12.3 OTHER CONSEQUENTIAL OR
SUPPORTIVE THERAPY 40 3.12.4 AREAS WHERE THERE IS INSUFFICIENT
INFORMATION TO MAKE RECOMMENDATIONS 40 3.12.5 PROPOSALS FOR FURTHER
STUDY 40 3.12.6 ADVERSE EFFECTS 40 3.12.7 RESTRICTIONS OF USE 40 3.13
MODEL INFORMATION SHEET 41 3.13.1 USES 41 3.13.2 DOSAGE AND ROUTE 42
3.13.3 PRECAUTIONS/CONTRAINDICATIONS 42 3.13.3.1 PHARMACEUTICAL
PRECAUTIONS 42 3.13.3.2 OTHER PRECAUTIONS 43 3.13.4 ADVERSE EFFECTS 43
3.13.5 USE IN PREGNANCY AND LACTATION 44 3.13.6 STORAGE 44 3.13.7
SPECIAL RISK GROUPS 44 3.14 REFERENCES 44 4. DANTROLENE SODIUM 49 4.1
INTRODUCTION 49 4.2 NAME AND CHEMICAL FORMULA OF ANTIDOTE 50 4.3
PHYSICO-CHEMICAL PROPERTIES 51 4.4 PHARMACEUTICAL FORMULATION AND
SYNTHESIS 52 4.5 ANALYTICAL METHODS 52 4.5.1 IDENTIFICATION AND
QUANTIFICATION OF DANTROLENE SODIUM AND ITS FORMULATION 52 4.5.2
QUANTIFICATION OF DANTROLENE IN BODY FLUIDS 53 VLLL 4.6 4.7 4.8 4.9 4.10
4.11 4.12 4.5.2.1 SPECTROFLUONMETRY 4.5.2.2 HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY SHELF LIFE GENERAL PROPERTIES ANIMAL STUDIES 4.8.1 4.8.2
4.8.3 PHARMACODYNAMICS 4.8.1.1 EFFECT ON SKELETAL MUSCLE 4.8.1.2 EFFECTS
ON OTHER TISSUES 4.8.1.3 STUDIES IN MALIGNANT HYPERTHERMIA- SUSCEPTIBLE
PIGS PHARMACOKINETICS TOXICOLOGY 4.8.3.1 ACUTE TOXICITY 4.8.3.2 SUBACUTE
TOXICITY 4.8.3.3 CHRONIC TOXICITY 4.8.3.4 TERATOGENICITY VOLUNTEER
STUDIES 4.9.1 4.9.2 4.9.3 4.9.4 ADMINISTRATION AND PLASMA CONCENTRATIONS
DISTRIBUTION 4.9.2.1 DISTRIBUTION TO THE FETUS AND NEWBORN BABY
ELIMINATION HUMAN IN VITRO PHARMACODYNAMICS CLINICAL STUDIES - CLINICAL
TRIALS CLINICAL STUDIES - CASE REPORTS 4.11.1 4.11.2 4.11.3 USE IN
MALIGNANT HYPERTHERMIA 4.11.1.1 PROPHYLAXIS OF MALIGNANT HYPERTHERMIA
4.11.1.2 PROPHYLAXIS OF MALIGNANT HYPERTHERMIA DURING PREGNANCY USE IN
NEUROLEPTIC MALIGNANT SYNDROME USE IN OTHER DRUG-INDUCED HYPERTHERMIA
SUMMARY OF EVALUATION 4.12.1 4.12.2 INDICATIONS 4.12.1.1 TREATMENT OF
MALIGNANT HYPERTHERMIA 4.12.1.2 TREATMENT OF NEUROLEPTIC MALIGNANT
SYNDROME 4.12.1.3 TREATMENT OF HYPERTHERMIA INDUCED BY MUSCLE RIGIDITY
IN POISONING ADVISED ROUTES AND DOSES 4.12.2.1 TREATMENT OF SEVERE
DRUG-INDUCED HYPERTHERMIA, INCLUDING MALIGNANT HYPERTHERMIA 53 53 53 54
54 54 54 55 55 55 55 55 56 56 56 57 57 57 57 58 58 58 59 59 59 60 61 61
62 62 62 62 62 63 63 IX 4.12.3 4.12.4 4.12.5 4.12.6 4.12.7 4.13 MODEL
4.13.1 4.13.2 4.13.3 4.13.4 4.13.5 4.13.6 4.13.7 4.12.2.2 PROPHYLAXIS OF
MALIGNANT HYPERTHERMIA PRIOR TO ANAESTHESIA IN SUSCEPTIBLE PATIENTS
OTHER CONSEQUENTIAL OR SUPPORTIVE THERAPY CONTROVERSIAL ISSUES AND AREAS
OF INSUFFICIENT INFORMATION PROPOSALS FOR FURTHER STUDIES ADVERSE
EFFECTS 4.12.6.1 HEPATOXICITY 4.12.6.2 INTERACTION WITH CALCIUM
ANTAGONISTS RESTRICTIONS FOR USE INFORMATION SHEET USES AS AN ANTIDOTE
DOSAGE AND ROUTE PRECAUTIONS AND CONTRAINDICATIONS PHARMACEUTICAL
INCOMPATIBILITIES AND DRUG INTERACTIONS ADVERSE EFFECTS USE IN PREGNANCY
AND LACTATION STORAGE 4.14 REFERENCES APPENDIX I LIST OF ANTIDOTES
APPENDIX II PRINCIOLES FOR THE EVALUATION OF ANTIDOTES 63 63 64 65 65 66
66 66 66 66 67 67 68 68 68 68 69 77 85 APPENDIX III PROFORMA FOR
MONOGRAPHS ON ANTIDOTES FOR SPECIFIC TOXIC AGENTS 91
|
| any_adam_object | 1 |
| author | Meredith, T. J. |
| author_facet | Meredith, T. J. |
| author_role | aut |
| author_sort | Meredith, T. J. |
| author_variant | t j m tj tjm |
| building | Verbundindex |
| bvnumber | BV009561261 |
| callnumber-first | R - Medicine |
| callnumber-label | RM302 |
| callnumber-raw | RM302.2 |
| callnumber-search | RM302.2 |
| callnumber-sort | RM 3302.2 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | XI 2800 |
| ctrlnum | (OCoLC)28749084 (DE-599)BVBBV009561261 |
| dewey-full | 615.9/08 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.9/08 |
| dewey-search | 615.9/08 |
| dewey-sort | 3615.9 18 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | 1. publ. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02300nam a2200613 cb4500</leader><controlfield tag="001">BV009561261</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19940506 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">940502s1993 |||| 10||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">052145459X</subfield><subfield code="9">0-521-45459-X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)28749084</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009561261</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM302.2</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.9/08</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 2800</subfield><subfield code="0">(DE-625)152989:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meredith, T. J.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Naloxone, flumazenil and dantrolene as antidotes</subfield><subfield code="c">scientific ed. T. J. Meredith ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">1. publ.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge</subfield><subfield code="b">Cambridge Univ. Press</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV, 98 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series</subfield><subfield code="v">1</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidotes</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antidotes</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dantrolene</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Dantrolene</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Flumazenil</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Flumazenil</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Naloxone</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Naloxone</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antidot</subfield><subfield code="0">(DE-588)4142655-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Flumazenil</subfield><subfield code="0">(DE-588)4225907-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Dantrolen</subfield><subfield code="0">(DE-588)4219898-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Naloxon</subfield><subfield code="0">(DE-588)4202897-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antidot</subfield><subfield code="0">(DE-588)4142655-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Dantrolen</subfield><subfield code="0">(DE-588)4219898-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Antidot</subfield><subfield code="0">(DE-588)4142655-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Flumazenil</subfield><subfield code="0">(DE-588)4225907-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Antidot</subfield><subfield code="0">(DE-588)4142655-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Naloxon</subfield><subfield code="0">(DE-588)4202897-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series</subfield><subfield code="v">1</subfield><subfield code="w">(DE-604)BV009560031</subfield><subfield code="9">1</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006318093&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006318093</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV009561261 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T17:37:10Z |
| institution | BVB |
| isbn | 052145459X |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006318093 |
| oclc_num | 28749084 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XV, 98 S. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Cambridge Univ. Press |
| record_format | marc |
| series | International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series |
| series2 | International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series |
| spelling | Meredith, T. J. Verfasser aut Naloxone, flumazenil and dantrolene as antidotes scientific ed. T. J. Meredith ... 1. publ. Cambridge Cambridge Univ. Press 1993 XV, 98 S. txt rdacontent n rdamedia nc rdacarrier International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series 1 Antidotes Antidotes therapeutic use Dantrolene Dantrolene therapeutic use Drug antagonists Flumazenil Flumazenil therapeutic use Naloxone Naloxone therapeutic use Antidot (DE-588)4142655-1 gnd rswk-swf Flumazenil (DE-588)4225907-1 gnd rswk-swf Dantrolen (DE-588)4219898-7 gnd rswk-swf Naloxon (DE-588)4202897-8 gnd rswk-swf (DE-588)1071861417 Konferenzschrift gnd-content Antidot (DE-588)4142655-1 s Dantrolen (DE-588)4219898-7 s DE-604 Flumazenil (DE-588)4225907-1 s Naloxon (DE-588)4202897-8 s International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series 1 (DE-604)BV009560031 1 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006318093&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Meredith, T. J. Naloxone, flumazenil and dantrolene as antidotes International Programme on Chemical Safety: IPCS, CEC Evaluation of antidotes series Antidotes Antidotes therapeutic use Dantrolene Dantrolene therapeutic use Drug antagonists Flumazenil Flumazenil therapeutic use Naloxone Naloxone therapeutic use Antidot (DE-588)4142655-1 gnd Flumazenil (DE-588)4225907-1 gnd Dantrolen (DE-588)4219898-7 gnd Naloxon (DE-588)4202897-8 gnd |
| subject_GND | (DE-588)4142655-1 (DE-588)4225907-1 (DE-588)4219898-7 (DE-588)4202897-8 (DE-588)1071861417 |
| title | Naloxone, flumazenil and dantrolene as antidotes |
| title_auth | Naloxone, flumazenil and dantrolene as antidotes |
| title_exact_search | Naloxone, flumazenil and dantrolene as antidotes |
| title_full | Naloxone, flumazenil and dantrolene as antidotes scientific ed. T. J. Meredith ... |
| title_fullStr | Naloxone, flumazenil and dantrolene as antidotes scientific ed. T. J. Meredith ... |
| title_full_unstemmed | Naloxone, flumazenil and dantrolene as antidotes scientific ed. T. J. Meredith ... |
| title_short | Naloxone, flumazenil and dantrolene as antidotes |
| title_sort | naloxone flumazenil and dantrolene as antidotes |
| topic | Antidotes Antidotes therapeutic use Dantrolene Dantrolene therapeutic use Drug antagonists Flumazenil Flumazenil therapeutic use Naloxone Naloxone therapeutic use Antidot (DE-588)4142655-1 gnd Flumazenil (DE-588)4225907-1 gnd Dantrolen (DE-588)4219898-7 gnd Naloxon (DE-588)4202897-8 gnd |
| topic_facet | Antidotes Antidotes therapeutic use Dantrolene Dantrolene therapeutic use Drug antagonists Flumazenil Flumazenil therapeutic use Naloxone Naloxone therapeutic use Antidot Dantrolen Naloxon Konferenzschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006318093&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV009560031 |
| work_keys_str_mv | AT meredithtj naloxoneflumazenilanddantroleneasantidotes |